Oral Abstract Session 01 - Global HIV Vaccine Enterprise

SYMPOSIA SESSIONS
42
Symposia Sessions
Symposium 05: Mucosal Immunology
S05.03
The Current State of Mucosal Immunity Elicited By
Vaccines
R. Shattock 1
1Imperial College London, London, United Kingdom (Great
Britain)
The development of a successful vaccine against HIV is likely
to require induction of strong and long-lasting humoral and
cellular immune responses at the mucosal portal of virus entry.
Mucosal antibodies able to prevent initial target cell infection,
reinforced by cellular responses that can control or eliminate
the initial foci of infected cells may offer the best potential for
robust sterilizing protection against HIV acquisition. While the
design of vaccine strategies able to induce such responses may
be crucial to development of effective vaccines, little has been
done to define possible mucosal correlates of protection against
vaginal or rectal exposure. Indeed, to date, most human clinical
HIV vaccine trials have omitted to evaluate mucosal immune
responses and have focused only on parenterally administered
candidates. The observation that the modest protective efficacy
of the RV144 trial did not correlate with neutralization but V1/
V2 binding antibodies has generated speculation that nonneutralizing
antibodies may have had some impact on HIV
acquisition, most likely at the mucosal level. Indeed a range
of other effector functions such as viral aggregation, mucus
trapping, inhibition of transcytosis, antibody dependent cellular
cytotoxicity (ADCC), and Fc-mediated inhibition of infection may
all enhance mucosal protection by antibody. However there is a
lack of definitive data to establish that localized responses offer
additional benefit over and above effector functions mediated
by mucosal expression of systemic induced responses. Drawing
on the wider field of vaccinology this presentation will review
current understanding of how adjuvants, delivery strategies and
routes of immunization modify mucosal responses to vaccination
in humans and non-human primates and will assess the relative
strengths and weakness of different approaches as they relate to
mucosal protection against HIV acquisition.
AIDS Vaccine 2012
S05.04
Persistence Pays Off: Stringent Control And Potential
Clearance of AIDS Virus Infection by Persistent
Vaccine-Induced Effector Memory T Cells
L. Picker 1
1 Vaccine and Gene Therapy Institute,Oregon Health & Science
University, Portland, OR, USA
This presentation will discuss recent advances in understanding
the efficacy of CMV/SIV vaccine vectors in protection against
highly pathogenic SIV challenge.